Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

Pneumonia II: Pathophysiology

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:

Pneumonia III: Complications and Assessment

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pulmonary complications in patients with haematological malignancies treated at a respiratory ICU.

The European respiratory journal·1998

Same author

Subclavian vascular access stenosis in dialysis patients: natural history and risk factors.

Journal of the American Society of Nephrology : JASN·1998

Same author

ATP-sensitive K+ channel blocker glibenclamide and diaphragm fatigue during normoxia and hypoxia.

Journal of applied physiology (Bethesda, Md. : 1985)·1998

Same author

Prognostic significance of p53 gene mutations in squamous cell carcinoma of the lung.

Oncology reports·1998

Same author

[Behavioral evaluation of the unilateral lesion model in rats using 6-hydroxydopamine. Correlation between the rotations induced by D-amphetamine, apomorphine and the manual dexterity test].

Revista de neurologia·1998

Same author

[Estimation of cardiac vagal reserve by dynamic exercise in patients with recent myocardial infarction].

Archivos del Instituto de Cardiologia de Mexico·1998

Same journal

Beyond the 5th percentile: rethinking diagnostic thresholds in pulmonary function testing.

The European respiratory journal·2026

Same journal

A Transcriptomic Atlas of Chronic Lung Allograft Dysfunction.

The European respiratory journal·2026

Same journal

Risk of cancer and mortality in patients with interstitial lung diseases: Danish cohort study.

The European respiratory journal·2026

Same journal

Proposing a minimal important difference in NTproBNP in pulmonary arterial hypertension.

The European respiratory journal·2026

Same journal

Unlocking growth potential: Ivacaftor therapy and developmental gains in lung and height in a cohort study of children and young adults with cystic fibrosis.

The European respiratory journal·2026

Same journal

Decoding the Lymphangioleiomyomatosis (LAM) Niche Microenvironment <i>via</i> Integrative Analysis of Single Cell Multiomics and Spatial Transcriptomics.

The European respiratory journal·2026

See all related articles

Search research articles

Related Experiment Videos

Corticosteroids in severe pneumonia.

O Sibila¹, C Agustí, A Torres

¹Respiratory Dept, Son Dureta University Hospital, Palma de Mallorca, Spain.

The European Respiratory Journal

|August 2, 2008

Summary

This summary is machine-generated.

Corticosteroids may reduce mortality in severe pneumonia by decreasing inflammation. Further clinical trials are needed to determine optimal use and safety for this serious infection.

Related Experiment Videos

Area of Science:

Infectious Diseases
Critical Care Medicine
Pharmacology

Background:

Severe community- or hospital-acquired pneumonia has a high mortality rate (20-50%) that has not improved with current therapies.
Excessive inflammatory response, despite adequate antibiotic treatment, is linked to poor outcomes in severe pneumonia.
Corticosteroids may modulate the inflammatory response and potentially improve outcomes.

Purpose of the Study:

To investigate the potential role of acute corticosteroid administration in reducing mortality in severe pneumonia.
To explore the effects of glucocorticosteroids on lung inflammation and bacterial burden.

Main Methods:

Review of existing evidence, including a small randomized controlled study and experimental studies.
Analysis of in vitro investigations on glucocorticosteroid effects.

Main Results:

One small randomized controlled study showed 0% mortality in the corticosteroid intervention arm.
Experimental studies indicated that glucocorticosteroids can decrease lung inflammatory response and bacterial load.
In vitro studies support the anti-inflammatory and anti-bacterial effects of glucocorticosteroids.

Conclusions:

Acute corticosteroid administration shows promise for decreasing mortality in severe pneumonia.
Further controlled clinical trials are essential to establish optimal dosage, duration, and safety profiles.
Key areas for investigation include specific dosing, administration periods, titration, tapering, and side effects before widespread clinical adoption.